1. Home
  2. AIRE vs PHIO Comparison

AIRE vs PHIO Comparison

Compare AIRE & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

N/A

Current Price

$0.36

Market Cap

11.5M

Sector

N/A

ML Signal

N/A

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

N/A

Current Price

$0.77

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRE
PHIO
Founded
2021
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
10.1M
IPO Year
2023
2011

Fundamental Metrics

Financial Performance
Metric
AIRE
PHIO
Price
$0.36
$0.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 163.7K
62.5K
Earning Date
11-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 60.34
N/A
EPS
N/A
★ N/A
Revenue
★ $4,518,498.00
N/A
Revenue This Year
$196.12
N/A
Revenue Next Year
$79.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 376.42
N/A
52 Week Low
$0.16
$0.75
52 Week High
$3.98
$1.88

Technical Indicators

Market Signals
Indicator
AIRE
PHIO
Relative Strength Index (RSI) 24.68 34.99
Support Level $0.30 N/A
Resistance Level $1.62 $1.12
Average True Range (ATR) 0.06 0.07
MACD -0.01 -0.00
Stochastic Oscillator 6.94 16.72

Price Performance

Historical Comparison
AIRE
PHIO

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: